A focused supplier of SR-17018.

We are a research-material supplier, not a clinic, CRO, or therapeutic company. We do not run pharmacology studies and we do not consult on study design. We source, verify, and ship a single compound. The company is small by choice — a narrow focus lets us keep the quality process tight and the documentation consistent for research customers.

SR-17018 (CAS 2134602-45-0) as precision powder in 1 g, 5 g, and 20 g formats. Tablet formats and custom formulations are not currently offered. Bulk quantities beyond 20 g are available by request. See the SR-17018 research guide for compound background and the safety and handling page for laboratory guidance.

Every batch is third-party verified before it is released for sale. Identity and purity are determined by high-performance liquid chromatography against a qualified reference standard, and the SR-17018 assay is reported on the certificate of analysis. Our internal specification is ≥ 99% by HPLC, above the ≥ 98% minimum that has been common in the research-reagent market for this compound. Batches that fall below 99% are not released. A certificate of analysis is issued for every batch.

Analytical work is performed by an independent third party, not in-house. Current COAs are published on the Batch Results & COAs page.

We do not supply SR-17018 for human or veterinary consumption. We do not make therapeutic claims. We do not offer clinical advice, study design, or dosing guidance — for research applications, investigators should rely on the primary pharmacology literature and their own institutional review. SR-17018 is not approved for human use in any jurisdiction we are aware of.

Regulatory status varies by country and updates faster than our content review cycle. It is the research customer's responsibility to verify current classification before receipt. The research disclaimer lays out the scope of permitted use and buyer responsibilities.

The research-guide pages in the /sr-17018 cluster summarize the peer-reviewed pharmacology literature on biased μ-opioid receptor agonism. We write them because commercial summaries of SR-17018 have historically cited older work without reflecting the substantive reinterpretation the field underwent around 2020. Our goal is a compact, cited, up-to-date reference that a researcher can read before citing SR-17018 in their own work.

We have a commercial interest in SR-17018 — we sell it. That is a conflict, and we disclose it up front. Our editorial standards page documents which sources we cite, which we do not, how often pages are reviewed, how corrections are handled, and how we attempt to remain neutral where the literature is contested.

For order inquiries, content corrections, and scientific review requests, email info@sr17labs.com. Our corrections policy is on the editorial standards page.

Live chat is available at the bottom of every page during US business hours.